Featured Research

from universities, journals, and other organizations

New pyrimidine compounds may lead to improved treatments for childhood brain cancer

Date:
April 6, 2010
Source:
Sbarro Health Research Organization
Summary:
Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. A recent study shows that pyrazolo-[3,4-d]--pyrimidine-derivatives, designed to target Src, may be effective in interfering with the cell cycle and causing cancer cell death in medulloblastoma.

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

A recent study shows that pyrazolo-[3,4-d]-pyrimidine-derivatives, designed to target Src, may be effective in interfering with the cell cycle and causing cancer cell death in medulloblastoma. The results were published in FASEB (The Journal of the Federation of American Societies for Experimental Biology) and were funded by the Sbarro Health Research Organization Center for Biotechnology, a nonprofit group devoted to molecular and genetic research located at the College of Science and Technology at Temple University in Philadelphia, PA and the Human Health Foundation, a nonprofit biotechnology research organization located in Terni, Italy.

"Our aim was to investigate the inhibitory effects of new pyrimidine-derivatives," said lead author Antonio Giordano, M.D. PhD, the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine and a 'Chiara fama' Professor at the Department of Human Pathology and Oncology, University of Siena, Siena, Italy. "Our findings show that, in medulloblastoma cells, pyrimidine derivatives can downregulate Src activity and reduce cell proliferation and tumor progression in vivo. This suggests that pyrimidine derivatives could be an effective therapeutic strategy not only for the treatment of medulloblastomas, but also for other Src expressing tumors."

Although better treatment regimens, including surgery, chemotherapy and radiotherapy have substantially improved survival, medulloblastoma remains incurable in about one third of patients and current treatments can cause toxic neurocognitive side effects.

"Compared with conventional chemotherapeutic agents cisplatin and etoposide that are presently used in medulloblastoma therapy, we found that these pyrimidine derivatives show major inhibitory effects on cell proliferation," said Alessandra Rossi, Ph.D, a co-author of the study, a Research Fellow at the Sbarro Institute. "Using these compounds with radiotherapy could allow the reduction of radiation doses and, consequently, the avoidance of radiotherapy-related cognitive and endocrine toxic effects. Moreover, our findings reveal that the pyrimidine compounds showed synergistic effects when combined with cisplatin and etoposide, suggesting their possible use in association with chemotherapy."

Attempts to further reduce the morbidity and mortality associated with medulloblastoma have been limited by the toxicity of conventional treatments and the low permeability of the blood-brain barrier (BBB), which restricts the entry of hydrophilic and large liphophilic compounds into the brain.

"Other Src inhibitors, currently in clinical trials for the treatment of other pathologies, showed low efficacy in the treatment of metastasis to the brain," said co-author Silvia Schenone, Ph.D, Associate Professor at the University of Genoa, Genoa, Italy, in collaboration with Maurizio Botta, Ph.D, Adjunct Professor at Temple University, Director, Drug Discovery Program, Professor Medical Chemistry and Dean of the Faculty of Pharmacy at the University of Siena, Siena, Italy. "But our pyrimidine derivatives have liphophilic characteristics, which enable them to pass through the blood brain barrier more easily, representing an other advantage of their use in medulloblastoma therapy."

Besides the possible use of these pyrimidine derivatives in the treatment of medulloblastoma, these compounds could be useful to develop new pharmacologic inhibitors to study the physiological and oncogenic functions of Src.


Story Source:

The above story is based on materials provided by Sbarro Health Research Organization. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rossi et al. New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. The FASEB Journal, 2010; DOI: 10.1096/fj.09-148593

Cite This Page:

Sbarro Health Research Organization. "New pyrimidine compounds may lead to improved treatments for childhood brain cancer." ScienceDaily. ScienceDaily, 6 April 2010. <www.sciencedaily.com/releases/2010/04/100406093512.htm>.
Sbarro Health Research Organization. (2010, April 6). New pyrimidine compounds may lead to improved treatments for childhood brain cancer. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2010/04/100406093512.htm
Sbarro Health Research Organization. "New pyrimidine compounds may lead to improved treatments for childhood brain cancer." ScienceDaily. www.sciencedaily.com/releases/2010/04/100406093512.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins